Diagnosis of spinal muscular atrophy in an SMN non-deletion patient using a quantitative PCR screen and mutation analysis

D W Parsons, P E McAndrew, P S Allinson, W D Parker Jr, A H M Burghes, T W Prior

Abstract
We report a child with clinical findings consistent with Werdnig-Hoffmann disease (spinal muscular atrophy type I) who was found not to have the homozygous absence of the survival motor neurone (SMN) gene observed in ~95% of spinal muscular atrophy patients. A quantitative PCR based dosage assay for SMN copy number showed that this patient possessed a single copy of the SMN gene. Heteroduplex and sequence analysis of the remaining copy of SMN showed a 2 base pair deletion within exon 4 which produces a frameshift and premature termination of the deduced SMN protein. This protocol of initial SMN gene dosage analysis followed by mutation detection allows identification of SMA compound heterozygotes (patients lacking one copy of SMN and having another mutation in their other copy), thereby increasing the sensitivity of SMA molecular diagnosis. (J Med Genet 1998;35:674–676)

Keywords: spinal muscular atrophy; survival motor neurone gene; quantitative PCR

Proximal spinal muscular atrophy (SMA) is an autosomal recessive neuromuscular disorder characterised by destruction of a motor neurones in the anterior horn of the spinal cord. SMA has an estimated incidence of 1 in 10 000 live births, with a carrier frequency of ~1 in 50 people.1 Childhood onset SMA is classified into three groups on the basis of age of onset and clinical course; type I SMA (Werdnig-Hoffmann disease) is the most severe form, with onset before the age of 6 months and death generally occurring within the first two years. In 1995, three cDNAs that detect deletions in the SMA critical region on 5q12-13 were reported.1-3 One of these, the survival motor neurone (SMN) cDNA, is encoded by two nearly identical genes, telomeric SMN (SMNt) and centromeric SMN (SMNc), which are distinguished only by single base changes in exons 7 and 8. Exon 7 of the SMNc gene is not detectable in ~95% of SMA patients.1 In those SMA patients retaining SMNc, a limited number of other small SMNt mutations have been identified.1-15

Case report
The proband, a male infant, was born to non-consanguineous parents at 38 weeks by induced vaginal delivery because of non-progression. The mother was 30 years old and the father was 32 years old at the time of birth, and their family history was unremarkable. Both the pregnancy and delivery were uncomplicated.

At 4 months of age, the patient was referred to a paediatric neurologist because of diffuse hypotonia and weakness. On examination, he was unable to lift his head or his legs off the bed. More movement was seen in the upper extremities; he was able to flex his arms and place his hands in his mouth bilaterally. No evidence of fasciculations or atrophy was noted, and no deep tendon reflexes were observed. Laboratory values, including creatine kinase, plasma amino acids, and urine organic acids, were within normal limits.

Nerve conduction studies of the right upper extremity showed extremely low amplitude motor responses. Repetitive stimulation of the right ulnar nerve at 2 Hertz and 50 Hertz failed to show a decremental or incremental response. Needle examination of selected limb muscles showed significantly reduced recruitment of motor unit potentials in all muscles examined; occasional fibrillations were seen in several muscles. These studies were interpreted as indicating electrophysiological evidence of a widespread motor neuropathic process, compatible with a clinical diagnosis of spinal muscular atrophy. No evidence of a myopathy or disorder of neuromuscular transmission was identified.

At 7 months of age, the patient suffered cardiopulmonary arrest. After resuscitation, a head CT was obtained that showed no bleeding or oedema. His neurological examination was notable for fixed pupils, negative corneal reflexes, oculocephalic reflexes, negative cold calorics, no cough reflex, no gag reflex, and no response to pain. It was clear that he had sustained a severe anoxic brain injury, and his parents agreed to discontinuation of support. Necropsy was declined.

Results
The clinical history, neurological examination, and nerve conduction studies were judged to be consistent with a motor neuron disease, most likely spinal muscular atrophy.

However, direct genetic testing for SMA did not show the homozygous absence of the SMNt gene which is found in ~95% of SMA patients.1-14 Owing to the strong clinical suspicion that this patient had SMA, more extensive molecular studies were undertaken.

A quantitative PCR assay for accurately determining SMNt gene copy number has
Diagnosis of spinal muscular atrophy in an SMN non-deletion patient

been developed in our laboratory.\(^\text{10}\) Although this assay has primarily been used for determination of SMA carrier status, it is also valuable for identification of patients with clinical features consistent with SMA who are likely to be compound heterozygotes (patients with one SMN\(^T\) gene lost to deletion or sequence conversion and one SMN\(^T\) gene containing another type of mutation). This assay uses an exon of the cystic fibrosis transmembrane regulator (CFTR) gene as a standard to determine the copy number of the SMN\(^T\) and SMN\(^C\) genes, and incorporates the use of two internal standards (SMN-IS and CFTR-IS) to monitor the efficiency of the PCR reaction and to ensure that equal amounts of target genomic DNA are added to each tube. Since this test uses CFTR as the standard for determination of SMN\(^T\) copy number, the significant limitation of using the SMN\(^C\) gene (whose copy number varies in both patients and controls) as a reference is avoided. Dosage analysis of the SMN\(^T\) gene in the proband showed that he possessed only a single copy of SMN\(^T\) (fig 1).

Heteroduplex analysis was then used to screen for sequence variations in the nine exons of the remaining copy of SMN\(^T\).\(^\text{10}\) An abnormal band was identified in exon 4 of SMN. Sequence analysis of patient exon 4 subclones showed a two base pair deletion of nucleotides 542-3 (GT) of the SMN gene (fig 2). The deletion results in a frameshift and premature termination codon shortly downstream, predicting an SMN protein product containing eight altered amino acids before truncation. In order to determine whether the variant exon 4 sequence was contained within SMN\(^T\) or SMN\(^C\), the patient’s lymphocyte RNA was amplified by RT-PCR using an exon 4 sense primer and an exon 8 antisense primer, then subcloned and sequenced. Patient subclones containing SMN\(^T\) were identified by restriction enzyme digestion, and sequence analysis of these clones confirmed that the mutant transcripts were derived from SMN\(^C\). These results indicate that this type I SMA patient had two different SMN\(^T\) mutations: one SMN\(^T\) allele was deleted or converted, while the other contained a two base pair deletion in exon 4.

Discussion

The fact that exon 7 of the SMN\(^T\) gene is not detectable in \(-95\%\) of SMA patients has allowed the development of an effective PCR based assay for the diagnosis of SMA.\(^\text{3,4}\) However, the 1 in 20 SMA patients who do not homozygously lack the SMN\(^T\) gene will be missed using this test. The proband, a male infant with clinical findings consistent with a diagnosis of type I SMA (Werdnig-Hoffmann disease), is one of these patients. He inherited one deleted or converted copy of the SMN\(^T\) gene and one copy containing a different mutation, a 2 base pair deletion in exon 4 which causes a frameshift and would be predicted to result in a truncated SMN\(^T\) protein.

We have previously reported a quantitative PCR based assay for determination of SMN\(^T\) gene copy number.\(^\text{10}\) In addition to allowing the molecular diagnosis of SMA carriers, this test also enables us to screen patients with SMA-like clinical findings efficiently in order to help distinguish SMA compound heterozygotes from non-5q cases. Once an SMA-like patient with one copy of the SMN\(^T\) gene has been identified, the probability of a 5q SMA diagnosis is increased significantly. However, it is possible that the subject may be an SMA
carrier whose symptoms are caused by another neuromuscular disorder. Therefore, we recommend that mutation screening of the remaining copy of SMN² be carried out. By using this initial quantitative screen for SMN² gene copy number, the number of patients who require molecular diagnosis can be drastically reduced. In our experience, ~10% of the patients referred to our diagnostic laboratory for SMA testing who are not homozgyously lacking the SMN² gene retain a single copy of SMN². In the remaining 90% of these SMA-like patients, the SMN² gene dosage is normal and 5q SMA is effectively ruled out as a diagnosis; in these cases the physician should consider other neuromuscular diseases. We have used this combination of an initial SMN² dosage assay and mutation detection to identify two other small mutations in the SMN² gene, a missense mutation (S262D) and an 11 base pair duplication in exon 6. Once a specific SMN² mutation has been identified in a family, other family members can be accurately diagnosed and appropriately counselled.

This screening strategy would not be as useful in diagnosing SMA in consanguineous families or in groups exhibiting a significant founder effect, since subjects who are homozygous for a non-deletion SMN² mutation would be more common in those instances. Another limitation is that mutation detection in the SMN² gene is relatively technically difficult. Although a few of the SMN² mutations identified have now been found in more than one patient, there is no single common mutation which can be tested. In addition, SMN² mutations have been identified in at least four different exons of the gene; there is not one mutational hotspot which could be easily screened. The presence of the copy gene (SMN²) also complicates SMN² mutation detection. Since SMN² and SMN¹ are only distinguished by single nucleotide sequence changes in exons 7 and 8, either RFLP-PCR or long PCR based strategies must be used to show that any mutation identified exists in SMN² and not SMN¹. Although mutation analysis of the SMN² gene is not as straightforward as for some genes, the actual quantity of patients to be screened is significantly reduced by the initial dosage assay and the number of SMN² exons to be analysed (nine) is feasible. This protocol of initial SMN² gene dosage analysis followed by mutation detection allows identification of SMA compound heterozygotes (patients lacking one copy of SMN² and having another mutation in their other copy), thereby increasing the sensitivity of SMA molecular diagnosis.

We are grateful to all of the SMA families who have so kindly participated in our studies. This research was funded by grants from the Muscular Dystrophy Association (MDA) and Families of SMA. We are also grateful for the photographic assistance of Arthur Weeks in preparation of this manuscript.

Diagnosis of spinal muscular atrophy in an SMN non-deletion patient using a quantitative PCR screen and mutation analysis.

D W Parsons, P E McAndrew, P S Allinson, W D Parker, Jr, A H Burghes and T W Prior

*J Med Genet* 1998 35: 674-676
doi: 10.1136/jmg.35.8.674

Updated information and services can be found at:
http://jmg.bmj.com/content/35/8/674

**Email alerting service**

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Notes**

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/